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ABSTRACT 
Tau pre-mRNA contains a stem-loop structure involved in the r gulation of the alternative 
splicing of tau protein. We describe here a new family of Tau RNA ligands selected by 
dynamic combinatorial chemistry based on the combinatio  of ametantrone with small 
RNA-binding molecules. The most promising compound results from derivatization of one 
of the side chains of the anthraquinone ring with the small aminoglycoside neamine 
through a short spacer. This compound binds the RNA target with high affinity in a 
preferred binding site, in which the heteroaromatic moiety intercalates in the bulged region 
of the stem-loop and its side chains and neamine interact with the major groove of the 
RNA. Importantly, binding of this compound to mutated RNA sequences involved in the 
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onset of some tauopathies such as FTDP-17 restores their thermodynamic stability to a 
similar or even higher levels than that of the wild-type sequence, thereby revealing its 

























RNA molecules, not only mRNAs or pre-mRNAs but also the wide variety of non-coding 
RNAs (e.g. miRNAs or their pre-miRNA precursors), are therapeutically relevant targets in 
medicinal chemistry.1 Like proteins, RNA folds local secondary structures ( .g. stem-loops, 
bulges, internal loops, etc.) into complex three-dimensional architectures, generating 
unique binding sites where small molecules can be accomodated.2 Owing to the ubiquity of 
RNA-mediated biological processes, targeting theraputically relevant RNA sequences 
with small molecules offers new opportunities to contr l RNA function and, for instance, to 
treat human diseases.3 Despite the progress made in recent years, the discovery of ligands 
with high affinity and sequence selectivity for a given RNA target and with desirable drug-
like properties, still remains a challenge. This is mainly a consequence of our poor 
understanding of RNA-ligand recognition principles which hinders the rational design of 
new compounds based on structural studies.3b,4 
The microtubule-associated protein tau is required for the polymerization and stability of 
microtubules, as well as for maintaining neuronal itegrity and axonal transport. Neuronal 
filamentous deposits of this protein have been found in patients suffering from 
neurodegenerative diseases, including Alzheimer’s disease and some tauopathies.5 
Alternative splicing of exons 2, 3, and 10 of the MAPT gene, which encodes for tau 
protein, gives rise to six isoforms with either three (3R) or four (4R) repeat domains, which 
differ in their relative ability to bind to microtub les. In general, the relative ratio of 4R to 
3R is close to one in healthy adult human brains. However, this ratio is found altered in 
many tauopathies. The importance of a well-defined st m-loop structure located at the exon 
10-5’ intron junction of Tau pre-mRNA as a regulatory element of alternative splicing has 
been established both in vitro and in vivo.6 Such studies revealed that the extent of exon 10 
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inclusion is inversely proportional to the stability of this local secondary structure. Some 
intronic mutations (named +3, +13, +14 and +16 in Scheme 1) found in patients with 
tauopathies, such as frontotemporal dementia with parkinsonism linked to chromosome 17 
(FTDP-17), decrease the stem-loop thermodynamic stability,7 leading to an increase in 
exon 10 inclusion and an overproduction of 4R tau isoforms compared to the 3R 
isoforms.6,7  
From a therapeutic point of view, it has been hypothesized that ligands that target the RNA 
secondary structure located at the exon 10-5’ intron junction of Tau pre-mRNA would have 
the capacity to restore the physiological balance of tau isoforms generated upon abnormal 
alternative splicing by increasing the thermodynamic stability of the mutated sequences. 
Moreover, such compounds would allow to study how lca  secondary RNA structures can 
influence the outcome of pre-mRNA splicing.8 In recent years, several ligands able to bind 
and stabilize wild type and mutated Tau stem-loop structure have been reported. Varani and 
collaborators described the three-dimensional structu e of the RNA complex with the 
aminoglycoside neomycin B.9 More recently, the anticancer drug mitoxantrone (Mtx in 
Scheme 1) was identified by Wolfe and collaborators in a high-throughput screening as a 
promising ligand.10 Subsequent NMR structural studies of the complex of mitoxantrone 
with Tau RNA revealed that the anthraquinone ring of this drug intercalates between the 
two G:C base pairs flanking the bulged adenine.11 In addition, the evaluation of the binding 
to Tau RNA and the stabilization capacity of a series of mitoxantrone analogues allowed to 
establish structure-activity relationships.12 
In previous works,13 we used dynamic combinatorial chemistry (DCC)14 to identify a series 
of ligands that bind the Tau stem-loop structure with h gh to medium affinities, showing the 
desired ability to stabilize both wt and mutant RNA sequences upon binding. The most 
5 
 
promising RNA-templated ligands combined planar heteroaromatic rings such as acridine 
with neamine (Acr-Nea/Nea2 in Scheme 1B),13a a small aminoglycoside that incorporates 
rings I and II of neomycin, which are important structural motifs in RNA recognition. 
Guanidinylation of the neamine moiety had an important effect, improving not only the 
binding affinity of the ligands, but also their ability to stabilize the mutated sequences.13b 
Biophysical studies showed that these ligands interac  with RNA via intercalation of the 
acridine moiety, probably at the bulged region of the stem-loop structure, and that the 
combination with the aminoglycoside improves RNA binding properties of the 
heteroaromatic moiety.13 
On the basis of all these precedents, we wondered wh ther replacement of acridine by 
mitoxantrone in acridine-neamine compounds would lea  to Tau pre-mRNA ligands with 
enhanced RNA-binding properties and, more importantly, if ligands incorporating this 
anthraquinone moiety would maintain the preferred bin ing site of mitoxantrone at the 
bulged region of the stem-loop structure of Tau RNA. According to the reported structural 
data,11 the phenolic hydroxyl groups of mitoxantrone do not seem to have an important 
function in the recognition of Tau RNA.11,12 Consequently, instead of mitoxantrone, we 
selected ametantrone, an anthraquinone analogue (Amt in Scheme 1) with a proven lower 
cytotoxicity in eukaryotic cells.15 Since both side chains of mitoxantrone play an important 
role in the recognition of the stem-loop structure, in particular the ammonium functions,11 
we planned to use the end of one of the side chains of ametantrone as a derivatization point 
to attach the aminoglycoside moiety. Hence, we report here new Tau RNA ligands based on 
the derivatization of ametantrone with small RNA binding molecules (azaquinolone and 
neamine) (Scheme 1C), together with several spectroscopic studies (UV-Vis, fluorescence 





Scheme 1 (A) Sequences and secondary structure of wild-type (wt) and +3, +13, +14 and +16 
mutated Tau stem-loop RNAs. Exonic sequences are shown in capital letters and intronic sequences 
in lower case. Nucleotides involved in base pairs, p eviously identified by NMR, are connected by a 
dash.6a,11 When required, biotin or fluorescein derivatization was performed at the 5’ end. The ends 
of the chains were modified with 2’-O methylribonucleosides (denoted by an asterisk). (B) 
Structure of mitoxantrone, ametantrone and acridine-neamine ligands.13a (C) Schematic 








RESULTS AND DISCUSSION 
Selection of Tau RNA ligands 
In general, there is good correlation between the ligand’s amplification in dynamic 
combinatorial chemistry experiments and its binding affinity for a given biological target, 
either a nucleic acid (DNA or RNA) or a protein.14 Hence, prior to synthesizing 
ametantrone-neamine ligands, we planned to carry out a DCC experiment to validate our 
hypothesis by using thiol-derivatized building blocks. Ligand’s amplification might 
provide, in addition, valuable information about the optimal length of the spacer linking the 
two moieties. For this purpose, compounds with different distances between the reactive 
functional group and the building block core, such as the two neamine monomers shown in 
Fig. 1A, have been tested. 
To perform DCC experiments by using thiol-disulfide exchange reactions, a suitably-
modified ametantrone monomer, Amt-SH (Scheme 2), was required. We decided to replace 
the hydroxyl group of one of the side chains of ametantrone by a thiol group since this 
small modification was expected not to disturb the int raction with RNA. Ametantrone 
(Amt) was first synthesized following a reported procedure by reacting 1,4-
difluoroanthraquinone with an excess of N-(2-hydroxyethyl)ethylenediamine.16 After 
selective Boc-protection of the secondary alkyl amino functions, Mitsunobu reaction of 1 
with DIAD, PPh3 and thiolacetic acid afforded the thioacetate derivative (2) as a major 
product. Finally, Amt-SH was obtained after hydrolysis of the thioester group with sodium 
methoxide followed by an acidic treatment with TFA in the presence of TIS and water as 





Scheme 2 Synthesis of the thiol-derivatized ametantrone monomer (Amt-SH). 
 
The DCC experiment was carried out as previously report d.13a Briefly, the thiol-
derivatized monomers (Amt-SH, Acr-SH, Nea-SH, Nea2-SH, Azq-SH and TyrP-SH; see 
Fig. 1A for their structures) were incubated with the biotinylated wt Tau RNA in aqueous 
Tris–HCl buffer (50 mM, pH 7.7) containing NaCl (100 mM) and EDTA (0.1 mM) at room 
temperature, under an air atmosphere without stirring. These conditions ensure the correct 
folding of the RNA target as well as the thiol-disulfide exchange (21 theoretical compounds 
may be formed). After isolation of RNA and its interacting ligands with streptavidin 
anchored to magnetic beads, a hot acidic aqueous sol tion was used to denature it and to 
provoke the release of RNA-bound ligands. All the compounds were identified and 
quantified by UV-MS-HPLC (see Fig. 1B). The comparison with the control experiment 
(RNA free) allowed the determination of the % of amplification of the compounds in the 
presence of Tau RNA. As shown in Fig. 1C, disulfide heterodimers incorporating the 
ametantrone fragment were amplified in much higher ratio than those containing the 
acridine fragment, particularly when this heteroaromatic compound was combined with the 
neamine monomer: Amt-Nea (≈1600%) and Amt-Nea2 (≈3500%) vs Acr-Nea (≈50%) and 













































1) PPh3, DIAD, 0ºC, 30 min
2) 1, 0ºC, 30 min


























clearly indicated that ametantrone-containing ligands should have much higher binding 
affinity than those containing acridine.13a Interestingly, the amplification of Amt-Nea2 was 
about 2.2-fold higher than that of Amt-Nea. This reult reproduced the tendency previously 
found for Acr-Nea/Nea2 ligands, indicating that a shortest distance between the 
heteroaromatic fragment (acridine or ametantrone) ad the small aminoglycoside neamine 
is preferred in this family of Tau RNA ligands. 
 
On the basis of DCC results, we planned the synthesis of the Amt-Nea and Amt-Nea2 
ligands at higher scale to study their interaction with Tau RNA. Although Amt-Azq (Fig. 
1D) was amplified in a much lesser extent (≈200%) than ametantrone-neamine compounds, 
it was also selected because of the potential of the azaquinolone fragment to recognize the 
bulged adenine in the stem-loop.13a The synthesis of Amt-Nea/Nea2 and Amt-Azq was 
carried out in solution in a two-step process. First, one of the thiol-containing monomer 
(Nea/Nea2-SH or Azq-SH) was activated with 2,2’-dithiobis(5-nitropyridine) (DTNP) in a 
slightly acidic media.17 After reaction of the intermediates with the ametantrone-thiol 
monomer (Amt-SH), the expected disulfide heterodimers were isolated by reversed-phase 













Fig. 1 Results of a DCC experiment involving 5’-biotinylated wt Tau RNA and the Amt, Acr, Nea, 
Nea2, Azq and TyrP thiol-derivatized monomers. (A) Structure and peptide sequence of the 
building blocks. (B) HPLC traces showing the compositi n of the DCL in the absence (left) and 


















































































































































































































































































































































































(left) and the percentage changes (% amplification) of each species (right) in the presence of wt Tau 
RNA. (D) Structure of the selected ligands in the DCC experiment. 
 
In order to validate the results from the DCC experim nt, the binding affinities of the 
selected ligands (Amt-Nea/Nea2 and Amt-Azq) for Tau RNA were determined by 
fluorescence titration experiments by using the 5’-nd fluorescein-labelled 
oligoribonucleotide.14e As shown in Fig. 2A, the fluorescence of RNA was quenched upon 
addition of increasing concentrations of the ligand. A characteristic dose-dependent curve 
was obtained when the normalized fluorescence intensity at 517 nm was plotted versus of 
the compound concentrations. In all cases, the full titration was repeated in the absence of 
RNA to subtract the inherent fluorescence of the ligands from that of the labelled RNA. 
EC50 values, which can be assimilated to dissociation constants, were obtained by fitting 
the data to a sigmoidal dose-response curve (Fig. 2B). 
Fig. 2 (A) Fluorescence quenching of wt Tau RNA labelled with fluorescein upon addition of 
increasing concentrations of Amt-Nea2. Experimental conditions: [RNA] = 25 nM and [ligand] = 0 
to 614 nM, in 10 mM sodium phosphate buffer pH 6.8,100 mM NaCl and 0.1 mM Na2EDTA. (B) 




The normalized fluorescence was calculated by dividing the difference between the observed 
fluorescence, F’, and the initial fluorescence, F0, by the difference between the final fluorescence, 
Ff, and the initial fluorescence, F0. Hence, absolute values of the fluorescence changes upon ligand 
titration are shown. 
 
Table 1 Binding of the ligands to wt RNA in the absence or in the presence of a tRNA competitor. 
Ligand EC50 (nM)
a EC50 (nM) 
+tRNAb 
EC50+tRNA  
/ EC50  
Neamine 3.1x106 nd nd 
Mitoxantrone 168.8 + 6.2 803.3 4.8 
Ametantrone 231.8 + 8.0 675.6 2.9 
Amt-Azq 162.5 + 5.7 570.7 3.1 
Amt-Nea 78.8 + 6.1 714.2 9.1 
Amt-Nea2 70.6 + 7.2 569.8 8.1 
aFluorescence measurements were performed in 10 mM sodium phosphate buffer pH 6.8, 100 mM 
NaCl and 0.1 mM Na2EDTA, with a [RNA] = 25 nM. 
bMeasured in the presence of a 30-fold 
nucleotide excess of a mixture of tRNA (tRNAmix). 
 
The EC50 values of the ametantrone-containing ligands together with those of ametantrone, 
mitoxantrone and neamine are shown in Table 1. In good agreement with DCC results, the 
most amplified compounds exhibited the highest binding affinities. Indeed, ligands 
containing the ametantrone fragment showed EC50 values that fall into the nanomolar scale 
(EC50=78.8 and 70.6 nM for Amt-Nea and Amt-Nea2, respectiv ly). It is also noticeable 
that ametantrone-neamine ligands bind Tau RNA much stronger than any of their 
components alone (see the neamine and ametantrone entries in Table 1), which indicates 
that the derivatization of one of the ametantrone sid chains with a polycationic 
13 
 
aminoglycoside has a positive effect on binding affinity. Moreover, the binding was 
observed to be approximately two times stronger for Amt-Nea/Nea2 ligands than for 
mitoxantrone or Amt-Azq. Interestingly, a correlation was observed between the binding 
affinity and the linker length: the binding of Amt-Nea2 was slightly higher than that of the 
analogous compound with the longer spacer linking the ametantrone and neamine moieties 
(Amt-Nea). This is consistent with % amplification in DCC and with previous studies on 
Acr-Nea/Nea2 ligands.13a 
 
One of the main problems of RNA ligands based on small olecules is the achievement of 
sequence selectivity, sometimes referred to as specificity. 18 This is because the relatively 
low cellular expression level of disease-associated RNAs in comparison with ribosomal 
RNAs, which represent about 80–90% of the total RNA content of living cells.19 Hence, the 
ratio between the EC50 values in the presence and in the absence of large excess of tRNA
mix 
from baker’s yeast might provide an idea of the specificity of the ligand. As shown in Table 
1, ametantrone was found to be slightly more specific for Tau RNA than mitoxantrone. 
This result together with its reported low cytotoxicity15 supports the initial choice of 
ametantrone instead of mitoxantrone for developing new Tau RNA ligands. As expected, 
the combination of ametantrone with neamine afforded less specific ligands than the 
combination with azaquinolone. In the presence of the competitor, the EC50 values of Amt-
Nea and Amt-Nea2 for wt RNA were increased by 9-fold and 8-fold, respectively, whereas 
that of Amt-Azq was only increased by 3-fold. Interestingly, the specificity of the 
ametantrone-neamine ligands was significantly higher t an that previously found for 
acridine-neamine ligands, particularly in the case of the compound containing the shorter 
linker. Comparison of specificity ratios for Amt-Nea and Amt-Nea2 indicates that a shorter 
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spacer provides a slightly higher specificity. This trend is similar to that previously reported 
by Tor et al.18b with ligands for the HIV-1 RRE RNA target based on the combination of 
acridine with neomycin, but differs from that we found with Acr-neamine ligands.13a The 
overall results indicated that ametantrone not only generates ligands with higher affinity for 
Tau RNA than acridine upon combination with neamine, but that this anthraquinone 
derivative confers higher specificity on them, particularly when comparing ligands with the 
shortest spacer. 
 
Spectroscopic studies on the interaction of Amt-containing ligands with Tau RNA  
Our next objective was focused on the study of the interaction of ametantrone-containing 
ligands with Tau RNA by using several spectroscopic techniques (UV-Vis, fluorescence 
and NMR) in order to assess if this new family of cmpounds have a preferred binding site 
in the target. As previously stated for mitoxantrone, the presence of a bulged region in Tau 
RNA, where adenine is flanked by two G:C pairs, facilit tes the intercalation of the 
anthraquinone ring, causing the displacement of the bulged adenine and the establishment 
of sequence-specific contacts between the positively-charged side chains and the RNA 
nucleobases and phosphate groups.11 
First, the UV-visible absorption spectra and the fluorescence emission spectra (upon 
excitation at 547 nm) were recorded for all the comp unds (Amt, Amt-Azq and Amt-
Nea/Nea2, see Fig. 3 and Fig. S2-S3 in the Supplementary Information) in the absence and 
in the presence of increasing amounts of wt Tau RNA. As expected, strong hypochromic 
and bathochromic effects were observed in the UV-Vis spectra during the titration, which 
are consistent with binding of the heteroaromatic moiety through an intercalative 
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mechanism. The intensity of the two bands in the 450-700 nm region decreased gradually 
until saturation was reached (about 3.9 mol equiv. of RNA), with two maxima at 594 and 
642 nm (overall redshift of 12 and 16 nm, respectivly). A similar behaviour was found 
with Amt-Azq and Amt-Nea/Nea2, although the hypochrmic and batochromic effects 
were slightly more pronounced. Fluorescence titration experiments reproduced these 
results, although the quenching of the fluorescence was slightly higher for the ligands with 
smaller EC50 values, showing a parallelism with the binding affinity.  
Although these results are consistent with the intercalation of the anthraquinone 
chromophore in Tau RNA, the comparison with the behaviour previously reported for 
mitoxantrone11 and some acridine-containing ligands13a seems to suggest some differences 
in their binding mode. This might be attributed to a higher affinity for a specific and well-
defined binding site in the Tau RNA structure. As a consequence, these ligands would be 
allocated at their preferred binding site in the complex at a lower RNA/ligand ratio. More 
detailed information on the mode of interaction of ametantrone-containing ligands was 
obtained by NMR spectroscopy.20 
 
Fig. 3 UV-Vis spectra (A) and fluorescence emission spectra (B) of Amt-Nea2 in the absence and in 
the presence of increasing amounts of wt RNA in a 10 mM sodium phosphate buffer, pH 6.8, 
containing 100 mM NaCl and 0.1 mM Na2EDTA. 8.4 µM and 2 µM solutions of Amt-Nea2 were 
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used in UV-Vis and fluorescence titration experiments, respectively. The emission spectra were 
recorded from 600 ~ 850 nm with λex = 547 nm. 
 
Titration experiments of the ligands (Amt, Amt-Azq and Amt-Nea/Nea2) with Tau RNA 
were monitored by NMR (see Fig. 4A and Fig. S4-S5 in the Supplementary Information). 
Addition of Amt or Amt-Azq caused a general line broadening of all RNA signals, in 
particular those close to the bulged adenine (U0 and G-1). In contrast, titration with Amt-
Nea or Amt-Nea2 provoked very little line broadening, even in excess of ligand (Fig. 4 and 
S5). This different behaviour, and the observation of only one set of signals at 1:1 complex 
conditions, suggests that Amt-Nea/Nea2 bind to the target in a more defined binding site 
than the other compounds. As can be seen in Fig. 4A, at a RNA:Amt-Nea2 ratio of 1:0.5, 
different imino signals arising from the free and bound RNA could be observed. This 
indicates that both species are in slow equilibrium n the NMR time scale. 2D NMR 
experiments were carried out with the 1:1 complex Amt-Nea2:RNA. Provided the RNA 
concentration does not exceed 300 µM to avoid aggregation of the oligoribonucleotide, the 
resulting 2D spectra of Tau RNA and of the complex with the ligand were of sufficient 
quality to proceed with a more in-depth structural analysis. Some preliminary assignments 
could be obtained with standard 1H experiments (NOESY, TOCSY and DQF-COSY), 
facilitated by previous assignments on Tau RNA and Mtx-Tau RNA complex reported by 
Varani’s group.6a,11 To identify the region of the stem-loop structure more affected by the 
ligand, the exchangeable proton region was first examined since exhibits a favourable 
chemical shift dispersion (Fig. 4 and S6). Upon complex formation, the most pronounced 
changes in chemical shifts involved imino protons of G-1 and U0, which were shifted by –
0.88 and 0.36 ppm, respectively, compared with their values in the free RNA. In contrast, 
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imino signals of G+1 (∆δ= +0.1 ppm), U+2 (∆δ= +0.05 ppm) and G+3 (∆δ= –0.03 ppm) 
were not significantly affected in the complex. The imino proton signals of U+11 and G+5 
were rather broad in the free RNA and were not clearly detected in the complex. 
Interestingly, a new imino signal at 12.50 ppm appeared in the complex, which was 
assigned to G+17. This suggest that C-3:G+17 base pir is probably more dynamic and 
exposed to the solvent in the isolated RNA than in the complex with Amt-Nea2. 
 
Fig. 4 (A) Imino region of the NMR spectra of wt Tau RNA alone and in the presence of increasing 
amounts of Amt-Nea2. From bottom to top: ligand/RNA ratio = 0.0, 0.5, 1.0, 1.5 and 2.0. 
Assignments in gray are labelled according to Varani et al.11 Experimental conditions: [RNA]= 100 
µM, 10 mM phosphate buffer in H2O/D2O 90:10, pH= 6.8, T=5ºC. (B) Exchangeable protons region 
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of the NOESY spectrum (tm=100 ms) of the 1:1 complex Amt-Nea2:wt Tau RNA in H2O/D2O 9:1 
in 10 mM phosphate buffer, pH=6.8, T=5ºC. [Tau RNA]= 280 µM. RNA and Amt-Nea2 proton 
signals are labelled according to the numbering schemes shown in Scheme 1 and Fig. 1D, 
respectively. 
 
Regarding the ligand, some diagnostic signals were also easily distinguished in the NMR 
spectra of the complex. As shown in Fig. 4, two signals in the exchangeable proton region 
(δ = 9.92 and 9.52 ppm) corresponding to the amino protons NH(11) and NH(18) (see Fig. 
1D for numbering) of the two side chains of the ametantrone moiety of the ligand were 
clearly observed. The two amino signals show numerous cross-peaks with other protons of 
the ligand (aromatic protons H2 and H3 and methylene protons of the side chains) and, 
importantly, with some exchangeable and non-exchange ble protons of RNA. A number of 
key intermolecular cross-peaks could be assigned: NH(18)Amt-
H2Amt/H3Amt/H41C+16/H42C+16/H8G+17/H1G+17, NH(11)-H2Amt/H3Amt/H8G-1 
and H41C+16-H2Amt/H3Amt (Fig. 4B and S6 in the Supplementary Information). In 
addition, numerous cross-peaks between the Amt-Nea2 side chains protons and the 
aromatic protons of the RNA were observed (Fig. S7)Although at this stage the sequential 
assignment of the later ones is still ambiguous, these contacts indicate that the side chains 
interact with the RNA through the major groove. Most neamine protons are in the 3.3–4.1 
ppm region, but no intermolecular NOEs with the RNA could be found. However, the sign 
and intensity of NOE cross-peaks between neamine protons indicates that this moiety 
maintains the same correlation time than the rest of the complex, and is not dangling 
independently. Most probably, the neamine interacts mainly with the ribose-phosphate 
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backbone of the RNA, given rise to intermolecular cross-peaks that lie in very crowded 
regions of the NOESY spectra.  
In summary, NMR data are consistent with a mode of interaction in which the ametantrone 
moiety of the ligand interacts with the bulged region of the RNA stem-loop structure, most 
probably occupying the same site than mitoxantrone.11 The structural determination of the 
complex Tau RNA:Amt-Nea2 is out of the scope of this work, since it requires a complete 
resonance assignment and the extraction of a full set of distance constraints, only possible 
with isotopic-labelling (13C, 15N and probably partial deuteration of riboses). Such study is 
now in progress and it will be presented in due course. However, a feasible model of the 
complex can be spotted on the basis of the previously reported complex between Tau RNA 
and mitoxantrone,11 and the experimental information obtained here (Fig. 5 and S8). In this 
model, the anthraquinone ring is intercalated betwen G(–1):C(+16) and C(–3):G(+17) base 
pairs, and the two side chains of ametantrone and the neamine moiety lie into the major 
groove of the double helical segment. The extensive contacts between the side chains of 
Amt and the spacer with the RNA probably contribute to the enhanced binding affinity of 
this ligand for Tau RNA and favour the formation of a unique complex in contrast to that 





Fig. 5 Model of the 1:1 complex Tau RNA:AmtNea2. Coordinates for the Tau RNA:Mtx complex 
determined by Varani et al.11 were used to build the model, as described in the Experimental 
Section. 
 
As an additional check of the preference of ametantrone-neamine ligands for the Tau RNA 
bulged region, we explored the interaction of this ligand with two variants of the A-site 
RNA fragment: the native sequence, which contains an internal bulged region where 
aminoglycosides can be accommodated, and a mutant sequence lacking the internal bulged 
adenine. As shown in Fig. S13 (see the Supporting Information), the imino region of the 
NMR spectra of either the A-site sequence or its mutant analogue did not change 
significantly in the presence of increasing amounts of Amt-Nea ligands (up to 1.5 mol 
equiv.). Moreover, no signals from the ametantrone sid chain amino groups were observed 
in the exchangeable proton region of these spectra. These results clearly differ from those 
obtained with Tau RNA (see Fig. 3), supporting our conclusion that the bulged region of 
Tau RNA is a preferred binding site for the Amt-Nea lig nds described in this study. 
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Effect of Amt-containing ligands on the thermal stability of Tau RNA mutated 
sequences 
Once established that the derivatization of ametantrone with neamine generates ligands for 
Tau RNA with high binding affinity and a clear preference for the bulged region of the 
stem-loop structure, we focused on the evaluation of the impact of these compounds on the 
thermal stability of Tau RNA by UV-monitored melting experiments.14e As previously 
stated, effective ligands for Tau RNA are expected to reverse the destabilization of the 
stem-loop structure caused by mutations associated wi h FTDP-17. The +3, +14 and +16 
mutated sequences (see Scheme 1) were considered in this study since they cause a 
significant destabilization with respect to the wt sequence (–15 ºC, –13 ºC and –7 ºC, 
respectively). As shown in Table 2 and Fig. S9-S12 (see the Supplementary Information), 
the ∆Tm values for the RNA sequences in the presence of ametantrone were lower (about 
2ºC) than those found for mitoxantrone, which is consistent with its lower binding affinity 
(see Table 1). Regarding the three ametantrone-containi g ligands selected in our study, all 
of them had a positive effect on the thermal stability of all RNAs, particularly when the 
anthraquinone derivative was combined with neamine. This stabilization is substantially 
higher than that obtained with neamine or ametantrone alone (see Table 2), which supports 
the participation of both moieties in the interaction with the target. Interestingly, the 
stabilizing effect of the ametantrone-neamine ligands was considerably higher than that of 
mitoxantrone (e.g. the ∆Tm values for the +3 and +14 mutated sequences in the presence of 
1 mol equivalent of mitoxantrone were +5.7 ºC and +4.6 ºC, respectively, whereas in the 
presence of the same amount of Amt-Nea2, the ∆Tm values were +12.9 ºC and +10.4 ºC, 
respectively). Moreover, the RNA stabilization caused by ametantrone-neamine ligands 
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was much higher than that of our previous ligands based on the combination of acridine 
with neamine.13a As shown in Table 2, the Tm value of wt Tau RNA was clearly increased 
in the presence of the ametantrone-neamine ligand with the shortest spacer (∆Tm=+8.9 ºC 
for Amt-Nea2 vs ∆Tm=+6.4 ºC for Amt-Nea). This tendency was also reproduced in the 
case of the mutated sequences and is in good agreement with previous results with acridine-
neamine ligands where a correlation between the ligand’s binding affinity for Tau mutants 
and thermal stabilization was found.13a 
 
Table 2 Melting temperatures (Tm, ºC) for the complexation of the ligands with Tau RNAs (1 µM 
both in RNA and in ligands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl and 0.1 mM 
Na2EDTA). 
 Tmwt ∆Tma Tm+3 ∆Tma Tm+14 ∆Tma Tm+16 ∆Tma 
No ligand 66.5+0.1 - 51.4+0.3 - 53.5+0.3 - 59.6+0.2  
Neamine 66.9+0.3 +0.4 51.5+0.5 +0.1 54.0+0.4 +0.5 60.1+0.3 +0.5 
Mitoxantrone 69.2+0.4 +2.7 57.1+0.5 +5.7 58.1+0.4 +4.6 63.4+0.6 +3.8 
Ametantrone 67.1+0.3 +0.5 54.2+0.5 +2.8 55.7+0.6 +2.2 61.6+0.4 +2.0 
Amt-Azq 67.8+0.6 +1.3 56.1+0.6 +4.7 57.3+0.3 +3.8 61.8+0.4 +2.2 
Amt-Nea 72.9+0.2 +6.4 60.7+0.4 +9.3 60.7+0.6 +7.2 66.5+0.5 +6.9 
Amt-Nea2 75.4+0.4 +8.9 64.3+0.5 +12.9 63.9+0.5 +10.4 69.4+0.4 +9.8 
a
∆Tm= (Tm of the RNA in the presence of ligand) – (Tm of RNA alone).  
 
Since the stability of RNA depends on the ionic strength and the most promising ligands 
(Amt-Nea/Nea2) are positively charged at physiological pH, we examined the influence of 
sodium ion concentration on the thermal stability of the target in the presence of these 
compounds.21 Melting curves of the most destabilized sequence, the +3 mutated RNA, were 
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recorded at two NaCl concentrations (50 mM and 150 mM) in the absence and in the 
presence of either ametantrone-neamine ligands or their isolated components (neamine or 
ametantrone). As expected, the stability of free RNA significantly increased with the Na+ 
concentration (Tm = 44.3, 51.4 or 52.5 ºC in 50, 100 or 150 mM NaCl, respectively). 
However, as shown in Fig. 6, the stability of the complexes clearly decreased upon 
increasing the Na+ concentration, which confirms the importance of the electrostatic 
interactions between these ligands and RNA. Interesingly, this behaviour was also found 
with ametantrone, which indicates that the stabilization provided by this anthraquinone 
derivative is not only based on intercalation but also on electrostatic interactions. This is in 
good agreement with the structure of the complex Mt-Tau RNA11 and with the NMR data 
on the interaction between Amt-Nea2 and Tau RNA report d in this work that reveals 
specific contacts between the amino functions of the side chains of the anthraquinone 
heteroaromatic fragment and RNA.  
 
Fig. 6 Comparison of the stabilizing effect of the ligands upon complexation with +3 mutated Tau 
RNA at different NaCl concentrations. Melting temperatures (Tm) were determined in 10 mM 
sodium phosphate buffer, pH 6.8, 0.1 mM Na2EDTA and NaCl at the concentration indicated, at 













































































In this work, we have described a new family of Tau RNA ligands based on the 
derivatization of one of the side chains of ametantrone with azaquinolone (Amt-Azq) or 
neamine (Amt-Nea/Nea2). All the reported compounds bind Tau RNA with low EC50 
values (nM scale), particularly those containing the aminoglycoside moiety (e.g. EC50= 
70.6 nM for Amt-Nea2). In addition, ametantrone-contai ing ligands are able to stabilize 
both wt Tau RNA and some of the mutated sequences associated with the development of 
tauopathies, such as FTDP-17. The overall data indicates that the derivatization of one of 
the side chains of ametantrone with neamine through a s ort spacer results in the compound 
with the best RNA-binding properties. This is consistent with the results from dynamic 
combinatorial chemistry experiments, and supports the choice of anthraquinone derivatives, 
such as ametantrone, as a starting point to synthesize ligands with improved Tau RNA-
binding properties. It is particularly relevant the ability of Amt-Nea2 to restore the 
thermodynamic stability of the mutated sequences upon complexation to a similar or even 
higher level than that of wt RNA. Moreover, NMR spectroscopic studies revealed the 
existence of a preferred binding site for this ligand to Tau RNA in which the anthraquinone 
fragment intercalates in the bulged region of the stem-loop structure, and the neamine 
moiety and the Amt side chains interact with the major groove of the RNA stem.  
Current efforts are underway to increase the cellular stability of the most promising ligand 
by replacing the disulfide linkage with a non-reversible isoster bond, as well as for 
elucidating by NMR spectroscopy the tridimensional structure of the complex between Tau 
RNA and Amt-Nea2. All these studies and the present work reported here will provide 
valuable information for designing new ametantrone-containing ligands with improved 
RNA-binding properties, not only for modulating Tau pre-mRNA splicing but also for 
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binding to other therapeutically relevant RNA secondary structures that contain a 
characteristic bulged region where an adenine nucleotid  is flanked by two G:C base pairs, 





Materials and Methods. Unless otherwise stated, common chemicals and solvents (HPLC 
grade or reagent grade quality) were purchased from co mercial sources and used without 
further purification. Aluminium plates coated with a 0.2 mm thick layer of silica gel 60 F254 
(Merck) were used for thin-layer chromatography analyses (TLC), whereas flash column 
chromatography purification was carried out using silica gel 60 (230-400 mesh).  
Reversed-phase high-performance liquid chromatography (HPLC) analyses of thiol-
derivatized monomers and ligands were carried out on a Jupiter Proteo C18 column 
(250x4.6 mm, 90 Å 4 µm, flow rate: 1 mL/min) using linear gradients of 0.045% TFA in 
H2O (A) and 0.036% TFA in ACN (B). In some cases, purification was carried out using 
the same analytical column. A semipreparative Jupiter Proteo column was used for the 
purification of some compounds (250x10 mm, 90 Å 10 µm, flow rate: 3 mL/min), using 
linear gradients of 0.1% TFA in H2O (A) and 0.1% TFA in ACN (B). 
NMR spectra were recorded at 25ºC on Varian spectrometers (500 or 600 MHz) using 
deuterated solvents. The residual signal of the solvent (CD3OD or D2O) was used as a 
reference in 1H and 13C spectra. Chemical shifts are reported in part per million (ppm) in 
the δ scale, coupling constants in Hz and multiplicity as follows: s (singlet), d (doublet), t 
(triplet), q (quadruplet), qt (quintuplet), m (multip et), dd (doublet of doublets), td (doublet 
of triplets), ddd (doublet of doublet of doublets), br (broad signal). 
High-resolution matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) 
mass spectra were recorded on a 4800 Plus spectrometer (ABSciex) both in positive (2,4-
dihydroxybenzoic acid matrix) or negative mode (2,4,6-trihydroxyacetophenone matrix 
with ammonium citrate as an additive). Electrospray ionization mass spectra (ESI-MS) 
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were recorded on a Micromass ZQ instrument with single quadrupole detector coupled to 
an HPLC, and high-resolution (HR) ESI-MS on an Agilent 1100 LC/MS-TOF instrument. 
Oligoribonucleotides were synthesized on an ABI 3400 DNA automatic synthesizer (1-
µmol scale) using 2’-O-tert-butyldimethylsilyl protection and following standar  
procedures (phosphite triester approach). RNA, biotin and fluorescein phosphoramidites, 
solid-supports, reagents and solvents for oligoribonucleotide synthesis were purchased from 
Glen Research or Link Technologies. RNase-free reagents, solutions and materials were 
used when manipulating oligoribonucleotides. RNase-fre  water was obtained directly from 
a Milli-Q system equipped with a 5000-Da ultrafiltration cartridge.  
Reversed-phase HPLC was used for the analysis and purification of the 
oligoribonucleotides using linear gradients of 0.1 M aqueous NH4HCO3, and a 1:1 mixture 
of 0.1 M aqueous NH4HCO3 and ACN. A Kromasil C18 column (250x4.6 mm, 10 µm, flow 
rate: 1 mL/min) was used for RNA analysis whereas a semipreparative Jupiter C18 column 
(250x10 mm, 300 Å 10 µm, flow rate: 3 mL/min) was used for purification at l rge scale. 
Characterization was carried out by high resolution MALDI-TOF MS (negative mode, 
THAP matrix with ammonium citrate). 
The following oligoribonucleotide sequences were synthesized (* label denotes that the 
ends of the chains were modified with 2’-O-methylribonucleosides): wt RNA: 
5’rG*C*GGCAGUGUGAGUACCUUCACACGUCC*C*; +3 mutated RNA: 
5’rG*C*GGCAGUGUAAGUACCUUCACACGUCC*C*; +14 mutated RNA: 
5’rG*C*GGCAGUGUGAGUACCUUCAUACGUCC*C*. +16 mutated RNA: 
5’rG*C*GGCAGUGUGAGUACCUUCACAUGUCC*C*. In fluorescence binding assays, 
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fluorescein was attached at the 5’-end of wt RNA. The following wt RNA sequence was 
used in NMR studies: 5’rGGCAGUGUGAGUACCUUCACACGUC. 
Synthesis of the thiol-derivatized ametantrone monomer (Amt-SH) 
1,4-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)anthraquinone (Ametantrone or Amt). 
1,4-difluoroanthraquinone (850 mg, 3.48 mmol) and N-(2-hydroxyethyl)ethylenediamine 
(3.5 mL, 34.8 mmol) were dissolved in dry pyridine (15 mL). After stirring for 72 h at RT 
under Ar, the reaction mixture, which acquired a deep blue colour, was evaporated in vacuo 
to dryness. The residue was dissolved in water (50 mL) and washed with diethyl ether (2 x 
50 mL). The aqueous phase was taken up and extracted sev ral times with 20% 
MeOH/CHCl3 until the blue colour disappeared (approx. 5 x 50 mL). Finally, the resulting 
organic phase was dried over anhydrous MgSO4, filtered and concentrated in vacuo to 
dryness to afford the crude of the expected compound, which was used without further 
purification in the following step. Rf (CHCl3/MeOH 7:3): 0.41; 
1H NMR (500 MHz, D2O) δ 
(ppm): 8.04 (2H, HG, HF, dd, J = 6.0 Hz, J = 2.9 Hz), 7.81 (2H, HE, HH, ddd, J = 6.0 Hz, J 
= 3.4 Hz, J = 0.8 Hz), 7.04 (2H, HB, HC, s), 3.93 (4H, HN, HN’ , m), 3.79 (4H, HK, HK’, t, J 
= 6.0 Hz), 3.43 (4H, HL, HL’ , t, J = 6.0 Hz), 3.34 (2H, HM, HM’ , m); MALDI-TOF MS, 
positive mode: m/z 413.5 (calcd mass for C22H29N4O4 [M+H]
+: 413.22), 435.6 [M+Na]+ 
(calcd mass for C22H28N4NaO4 [M+Na]
+: 435.20).  
1,4-Bis((2-((2-hydroxyethyl)-N-Boc-amino)ethyl)amino)anthraquinone (1). A solution of 
Boc2O (1.47 g, 6.75 mmol) in a 2:1 (v/v) mixture of dioxane/water (25 mL) was added to a 
solution of the crude of Amt and Na2CO3 (149.1 mg, 1.41 mmol) in a 2:1 (v/v) mixture of 
dioxane/water (75 mL). After stirring for 17 h at RT under Ar, the reaction mixture was 
evaporated in vacuo, and the residue was dissolved in ethyl acetate (75 mL). The resulting 
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organic phase was washed with water (3 x 75 mL), dried over anhydrous MgSO4, filtered 
and concentrated in vacuo to dryness. After flash column chromatography (gradient: 0-
100% AcOEt/hexanes; 0-2.5% MeOH/AcOEt), the desired pro uct was obtained as a blue 
solid (830 mg, 39 % (2 steps)). Rf (1 % MeOH in AcOEt): 0.23; 
1H NMR (500 MHz, 
CD3OD) δ (ppm): 8.28 (2H, HG, HF, m), 7.72 (2H, HE, HH, m), 7.56 (1H, HB/HC, s), 7.46 
(1H, HB/HC, m), 3.68 (8H, HN, HN’, HK, HK’ , m), 3.60 (4H, HL, HL’ , m), 3.37 (4H, HM, HM’ , 
m), 1.45 (9H, HO/HO’, HP/HP’, HQ/HQ’, s), 1.36 (9H, HO/HO’, HP/HP’, HQ/HQ, s); 
13C NMR 
(100 MHz, CD3OD) δ (ppm): 183, 157.43, 147.70, 135.69, 133.19, 133.18, 127.03, 125.05, 
110.84, 81.96, 61.39, 51.43, 49.35, 41.71, 28.73; HR-ESI MS, positive mode: m/z 613.3231 
(calcd mass for C32H45N4O8 [M+H]
+: 613.3232), 635.3062 [M+Na]+ (calcd mass for 
C32H44N4NaO8 [M+Na]
+: 635.3051).  
1-((2-((2-Hydroxyethyl)-N-Boc-amino)ethyl)amino)-4-((2-((2-(tioacetyl)ethyl)-N-Boc-
amino)ethyl)amino)anthraquinone (2). To a solution of PPh3 (17 mg, 0.65 mmol) in 
anhydrous THF (2 mL) under Ar, DIAD (129 µL, 0.65 mmol) was added at 0ºC. The 
formation of a white precipitate was observed after s ir ing for 2 h at this temperature. At 
this point, a solution of 1 (200 mg, 0.33 mmol) in anhydrous THF (6 mL) was added 
dropwise. After stirring for 10 min at 0ºC, thiolacetic acid (48 µL, 0.65 mmol) was added 
and the reaction mixture was stirred overnight at RT. The reaction mixture was 
concentrated in vacuo to dryness, dissolved in AcOEt (50 mL) and washed with water (3 x 
50 mL). The combined organic phases were dried overanhydrous MgSO4, filtered and 
concentrated in vacuo to dryness. After flash column chromatography (gradient: 0-100% 
AcOEt/hexanes; 0-5% MeOH/AcOEt), the desired product was obtained as a blue solid that 
was slightly impurified with triphenylphosphine oxide. Purification was finally 
accomplished by MPLC eluting with a gradient from 0 to 100 % of B (A: 0.1 % TFA in 
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H2O and B: 0.1 % TFA in H2O/ACN 3:7, 600 mL each solvent). Pure fractions by MS-
HPLC (linear gradient from 0 to 100 % B in 18 min; A: 0.1 % formic acid in H2O and B: 
0.1 % formic acid in ACN; Rt= 19.4 min) were combined and lyophilized, providing the 
desired product as a blue solid (79 mg, 36%). Rf (AcOEt): 0.68; 
1H NMR (500 MHz, 
CD3OD) δ (ppm): 8.28 (2H, HG, HF, m), 7.72 (2H, HE, HH, m), 7.54 (1H, HB/HC, m), 7.47 
(1H, HB/HC, m), 3.67 (10H, HK, HK’ , HM, HM’ , HN’, m), 3.39 (4H, HL, HL’ , m), 3.03 (m, 2H, 
HN), 2.29 (3H, HR, s), 1.46 (9H, HO/HO’, HP/HP’, HQ/HQ, s), 1.35 (9H, HO/HO’, HP/HP’, 
HQ/HQ, s); 
13C NMR (125 MHz, CD3OD) δ (ppm): 197.10, 183.25, 157.44, 147.66, 135.73, 
133.24, 127.06, 125.03, 110.93, 81.71, 61.39, 51.83, 47.98, 41.53, 30,71, 29.13, 27.16; 
MALDI-TOF MS, positive mode: m/z 671.3103 (calcd mass for C34H47N4O8S [M+H]
+: 
671.3109), m/z 693.2925 (calcd mass for C34H46N4NaO8S [M+Na]
+: 693.2929).  
1-((2-((2-Hydroxyethyl)amino)ethyl)amino)-4-((2-((2-
mercaptoethyl)amino)ethyl)amino)anthraquinone (Amt-SH). To a stirred solution of 
thioester derivative 2 (40 mg, 0.060 mmol) in MeOH (0.5 mL) was added sodium 
methoxide (240 µL, 1 M in MeOH, 0.24 mmol) and the mixture stirred for 1.5 h at RT 
under argon. Solvent was removed in vacuo and the resulting crude was dissolved in a 
TFA/TIS/H2O mixture (10 mL, 95:2.5:2.5) and allowed to stand for 30 min at RT. After 
evaporation in vacuo, the residue was dissolved in Milli-Q H2O (10 mL) and 1,4-
dithiothreitol (173 mg, 1.124 mmol) was added to the aqueous phase to reduce the disulfide 
bond of the resulting homodimeric compound. After stir ing for 24 h at 37ºC under Ar, the 
aqueous phase was washed with AcOEt (6 x 10 mL) to remove 1,4-dithiothreitol and 
lyophilized. Purification was carried out by MPLC eluting with a gradient from 0 to 100 % 
of B (A: 0.1 % TFA in H2O and B: 0.1 % TFA in H2O/ACN 3:7, 600 mL each solvent). 
Pure fractions by analytical HPLC (linear gradient from 0 to 70 % B in 30 min; A: 0.045 % 
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TFA in H2O and B: 0.036 % TFA in ACN; Rt= 17.9 min) were combined and lyophilized, 
providing the TFA salt of the desired product as a blue solid (4.6 mg, 12%). MALDI-TOF 
MS, positive mode: m/z 429.4 (calcd mass for C22H29N4O3S [M+H]
+: 429.20), m/z 451.4 
(calcd mass for C22H28N4NaO3S [M+Na]
+: 451.18); ESI MS, positive mode: m/z 429.03 
[M+H] +, m/z 451.08 [M+Na]+. 
Synthesis of ametantrone-containing ligands. 
Amt-Nea2.  2,2’-dithiobis(5-nitropyridine) (6.7 mg, 21.6 µmol) and Nea2-SH (1.7 µmol) 
were reacted in a 2:1 (v/v) mixture of THF/aqueous 0.1 % TFA (3 mL) under argon at RT. 
After 17 h, THF was evaporated in vacuo and the remaining blue solution was diluted with 
H2O (2 mL). The aqueous phase was extracted with Et2O (5 x 5 mL) to remove the excess 
of 2,2’-dithiobis(5-nitropyridine). Then, a solution of Amt-SH (1.4 µmol) in aqueous 0.1 % 
TFA (3 mL) was added and the mixture was stirred overnight under Ar at RT. After 
purification by semipreparative reversed-phase HPLC (linear gradient from 0 to 35 % B in 
30 min; A: 0.1 % TFA in H2O and B: 0.1 % TFA in ACN; flow: 3 mL/min; Rt= 23.7 min) 
and lyophilization, the desired product was obtained as a blue solid (0.78 µmol, 56 %). 1H 
NMR (600 MHz, D2O) δ (ppm): 8.25 (2H, HG, HF, m), 7.81 (2H, HE, HH, m), 7.49 (2H, HB, 
HC, s), 5.46 (1H, H1’, m), 4.02 (1H, Ha, m), 3.86 (5H, HN’ , H5’, H6, Ha’, m), 3.80 (4H, HK, 
HK’ , m), 3.72 (1H, H3’, m), 3.51 (2H, H6’, m), 3.38 (6H, H4, H5, HM’ , HM, m), 3.33 (1H, H4’, 
m), 3.21 (4H, HL, HL’ , m), 3.09 (2H, H1, H3, m), 3.02 (1H, H2’, m), 3.00 (2H, HN, m), 2.82 
(2H, Hb, m), 2.15 (1H, H2,eq, m), 1.48 (1H, H2,ax, m); HR-ESI MS, positive mode: m/z 
809.3671 (calcd mass for C36H57N8O9S2 [M+H]
+: 809.3690), m/z 831.3497 (calcd mass for 
C36H56N8NaO9S2 [M+Na]




Amt-Nea. 2,2’-dithiobis(5-nitropyridine) (11.6 mg, 37.5 µmol) and Nea-SH (3 µmol) were 
reacted in a 2:1 (v/v) mixture of THF/aqueous 0.1 % TFA (3 mL) under argon for 17 h at 
RT. After evaporation in vacuo and washings with Et2O, a solution of Amt-SH (1.7 µmol) 
in aqueous 0.1 % TFA (3 mL) was added and the mixture was stirred overnight under argon 
at RT. After purification by HPLC (see the conditions used for Amt-Nea2) and 
lyophilization, the desired product was obtained as a blue solid (0.57 µmol, 33 %). 1H 
NMR (600 MHz, D2O) δ (ppm): 8.32 (2H, HG, HF, m), 7.87 (2H, HE, HH, m), 7.57 (2H, HB, 
HC, m), 5.42 (1H, H1’, d, J = 3.7 Hz), 3.95 (3H, H5’, HN’, m), 3.85 (4H, HK, HK’ , m), 3.78 
(1H, Ha, m), 3.66 (1H, H3’), 3.59 (1H, Ha’, m), 3.50 (1H, H6), 3.45 (3H, HM, H4), 3.39 (4H, 
H5, H6’, H4’, m), 3.24 (4H, HL, HL’ , m), 3.18 (2H, HM’ , m), 2.99 (2H, H1, H3, m), 2.87 (3H, 
H2’, HN, m), 2.50 (2H, Hf, t, J = 7.1 Hz), 2.16 (1H, H2,eq, m), 1.43 (5H, Hb, He, H2,ax, m), 
1.10 (4H, Hc, Hd); HR-ESI MS, positive mode: m/z 865.4324 (calcd mass for C40H65N8O9S2 
[M+H] +: 865.4316); analytical HPLC (0 a 35% B en 30 min): Rt = 23.8 min). 
Amt-Azq. 2,2’-dithiobis(5-nitropyridine) (2.4 mg, 7.5 µmol) and Azq-SH (1.5 µmol) were 
reacted in a 1:1 (v/v) mixture of THF/1 M aqueous ammonium acetate pH=3.5 (4 mL) 
under argon at RT. After 5 h, THF was evaporated in vacuo and the remaining solution was 
diluted with H2O (2 mL). The aqueous phase was extracted with Et2O (5 x 5 mL) and 
lyophilized. A solution of Amt-SH in H2O-0.1 % TFA (2 mL) was added to the activated 
azaquinolone monomer dissolved in 1 M aqueous ammoniu  acetate pH=3.8 (3 mL) under 
Ar. After stirring for 3 h at RT, Amt-Azq ligand was isolated by semipreparative reversed-
phase HPLC (linear gradient from 0 to 40 % B in 30 min; A: 0.1 % formic acid in H2O and 
B: 0.1 % formic acid in ACN; flow: 3 mL/min; Rt= 16.2 min) and after lyophilization, the 
desired product was obtained as a blue solid (0.73 µmol, 48 %). 1H NMR (600 MHz, D2O) 
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δ (ppm): 7.98 (1H, HF/HG, m), 7.94 (1H, HG/HF, m), 7.75 (2H, HE, HH, m), 7.56 (2H, HW, 
HV, m), 7,22 (2H, HB, HC), 6.79 (1H, HU, d, J=8.0 Hz), 6.38 (1H, HX, d, J=9.5 Hz), 3.86 
(4H, HN’ , HT, m), 3.76 (2H, HK/HK’ , m), 3.64 (2H, HK/HK’ , m), 3.31 (4H, HL/HL’ , HQ, m), 
3.19 (4H, HL/HL’ , HM, m), 3.12 (2H, HM’ , m), 3.00 (4H, HO, HN, m), 2.93 (2H, HS, m), 2.68 
(2H, HP, m), 1.86 (2H, HR, m); HR-ESI MS, positive mode: m/z 747.3119 (calcd mass for 
C37H47N8O5S2 [M+H]
+: 747.3111), m/z 769.2945 (calcd mass for C37H46N8NaO5S2 
[M+Na]+: 769.2930); analytical HPLC (0 a 50% B en 30 min): Rt = 21.2 min). 
General procedure for the RNA-templated DCC experiments 
DCC experiments were carried out as previously described.13 Briefly, biotinylated wt RNA 
(6 nmol) was annealed in 240 µL of buffer (50 mM Tris-HCl, pH 7.7, 100 mM NaCl and 
0.1 mM Na2EDTA) by heating to 90ºC for 5 min and then slowly cooling to room 
temperature. After overnight incubation at RT, the solutions were stored at 4ºC. The 
annealed biotinylated RNA was added to an Eppendorf tube containing the quantified 
(Ellman’s test) thiol building blocks (24 nmol of each monomer), and the resulting mixture 
left to stand at RT under air without stirring. At the desired time, the disulfide exchange 
was stopped by the addition aqueous 0.1 % TFA (v/v) solution until pH ∼ 5–6 was reached. 
The biotinylated RNA and the binding ligands were isolated with streptavidin-coated 
magnetic beads (Biomag Streptavidin, 5 mg mL-1 suspen ion, Qiagen). A magnet was used 
in all washing procedures to retain the beads in the tube while the supernatant was pipetted 
off. The beads (500 µL of suspension for each DCL aliquot) were first washed with an 
acidic buffer (3 x 500 µL of 50 mM Tris-HCl, pH 5.8, 100 mM NaCl and 0.1 mM 
Na2EDTA). After incubation for 20 min at RT with the DCL aliquots, the beads were 
retained in the vessel using the magnet and the suprnatant solution was pipetted off again. 
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After washing the beads (3 x 200 µL of 50 mM Tris-HCl, pH 5.8, 100 mM NaCl and 0.1 
mM Na2EDTA) to remove the non-interacting compounds, a tre tment with a hot solution 
of 0.1% TFA in H2O (v/v) was used to liberate RNA-binding ligands (3 x 200 µL, 
incubation at 90ºC for 10 min). The three acidic soluti ns were combined and evaporated to 
dryness in a Speed-Vac to provide a residue that was dissolved in 0.1 % TFA in H2O (v/v) 
and analysed by UV-MS HPLC. Elution was performed on a Kinetex C18 column (100 x 
4.6 mm, 2.6 µm, 100 Å, flow rate: 0.2 mL min-1) with linear gradients of H2O and ACN 
containing both solvents, either 0.1% formic acid (v/v) or 0.1 % formic acid (v/v) and 0.01 
% TFA (v/v), to avoid the overlapping of some peaks nd to allow a more accurate 
integration. All peak areas of the HPLC traces were int grated and normalized taking into 
account the previously described extinction coefficients at 260 nm.13a The following 
extinction coefficient was calculated for ametantroe-containing compounds: ε260: 39.253 
M-1cm-1.  
Evaluation of the interaction between RNA and ligands 
All the assayed compounds displayed a purity ≥95%, determined by HPLC analysis. 
UV-monitored melting experiments: Melting curves were recorded as previously 
described.13a,13b Briefly, samples were cooled from 90ºC to 20ºC at a constant rate of 0.5 ºC 
min-1 and the absorbance at 260 nm was measured as a function of temperature. The 
denaturation curves (20ºC to 90ºC) were also recordd. All experiments were repeated at 
least three times until coincident Tm values were obtained. The estimated error in Tm 
values was ± 0.2ºC. The solutions were 1 µM both in RNA (wt, +3, +14 or +16) and in 
ligands, in 10 mM sodium phosphate buffer pH 6.8, 100 mM NaCl and 0.1 mM Na2EDTA.  
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UV-Vis and Fluorescence titration experiments: First, UV-Vis spectra or fluorescence 
emission spectra of the free ligand in the previous b ffer were recorded. Subsequent 
aliquots of a wt RNA solution in the same buffer (previously folded by heating the solution 
for 5 min to 90ºC and left to slowly cool to RT) were added to the ligand’s solution, and the 
UV-Vis or fluorescence emission spectra were recorded.  
Fluorescence binding assays: Fluorescence measurements were performed in 1-cm path-
length quartz cells on a QuantaMaster fluorometer (PTI) at 25ºC, with an excitation slit 
width of 4.8 nm and an emission slit width of 8 nm. Upon excitation at 490 nm, the 
emission spectrum was recorded over a range between 505 and 540 nm until no changes in 
the fluorescence intensity were detected. All binding assays were performed in the melting 
curves’ buffer. The sample was continuously stirred except during the fluorescence 
measurement. First, the fluorescence spectrum of the buffer was recorded, to be used as the 
baseline. For each experiment, the spectrum of a 25 nM solution of refolded fluorescein-
derivatized RNA (25 pmol in 1 mL buffer) was recorded, and the baseline blank subtracted. 
Subsequent aliquots of 1 µL of aqueous ligand’ solutions (of increasing concentrations, 
depending on the ligand’s affinity) were added to the RNA-containing solution. The 
fluorescence spectrum was recorded after addition of each aliquot until the fluorescein 
fluorescence signal at 517 nm reached saturation (typically 5–10 min). Over the entire 
range of ligand concentrations used, the emission maxi a varied less than 1 nm. The total 
volume of the sample never changed more than 10-15 %. The full titration was repeated in 
the absence of labelled RNA to correct for the presence of the ligand’s fluorescence. These 
spectra were subtracted from each corresponding point of the labelled RNA titrations, and 
the resulting fluorescence intensity was corrected for ilution (F’=F*V/V0).  
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The emission fluorescence at 517 nm was normalized by dividing the difference between 
the observed fluorescence, F’, and the initial fluorescence, F0, by the difference between the 
final fluorescence, Ff, and the initial fluorescence, F0. This normalized fluorescence 
intensity was plotted as a function of the logarithm of the total ligand concentration in each 
point of the titration. Finally, nonlinear regression using a sigmoidal dose-response curve 
was performed with the software package GraphPad Prism 4 (GraphPad Software, San 
Diego, CA) to calculate the EC50 values. Experimental errors were less than or equal to ± 
25% of each value.  
For competitive experiments, a tRNA from baker’s yeast (S. cerevisiae) was purchased 
from Sigma. Stock solutions of tRNAmix were quantified using an average extinction 
coefficient of 9.640 cm-1 per base.13a The fluorescence binding assays were carried out as 
described above with the exception that a 30-fold excess (base) of the tRNAmix was added 
to the refolded fluorescein-labelled RNA (or to thebuffer for the titration without target 
RNA). 
NMR Spectroscopy: NMR spectra were acquired in Bruker Advance spectrometers 
operating at 600 or 800 MHz, and processed with Topspin software. Samples were 
dissolved in 10 mM phosphate buffer, pH 6.8, either in D2O or in H2O/D2O 9:1.  
For titration experiments, wt RNA (60 nmol) was dissolved in 600 µL of 10 mM sodium 
phosphate buffer (pH 6.8), and 2 µL of a 33.3 µM solution of DSS in water were added. 
After lyophilization, the residue was dissolved in 600 µL of a 9:1 H2O/D2O mixture. 
Annealing was performed by heating at 90ºC for 3 min, followed by snap cooling on ice for 
20 min. NMR spectra were recorded at 5ºC to minimize the exchange with water. Water 
suppression was achieved by using an excitation sculpting sequence (zgesgp). Subsequent 
1D 1H NMR spectra were recorded at 5ºC upon addition of i creasing quantities of ligand 
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(0.5, 1.0, 1.5 and 2.0 mol equiv.). The total volume of the sample never changed more than 
5%.  
A 0.28 mM RNA sample (147 nmol in 525 µL sodium phosphate buffer) was used for 
recording 2D spectra in H2O/D2O at 5ºC. The complex with Amt-Nea2 was prepared by 
adding 1 mol equivalent of the ligand. A series of DQF-COSY, TOCSY and NOESY 
experiments were recorded in D2O. The NOESY spectra were acquired with mixing times 
of 100, 250 and 300 ms, and the TOCSY spectra were recorded with standard MLEV-17 
spin-lock sequence, and 80 ms mixing time. In addition, NOESY spectra in H2O were 
acquired with 100 ms mixing time. In 2D experiments i  H2O, water suppression was 
achieved either by using an excitation sculpting sequence or by including a WATERGATE 
module in the pulse sequence prior to acquisition. Two-dimensional experiments in D2O 
were carried out at temperatures ranging from 5 ºC to 25 ºC, whereas spectra in H2O were 
recorded at 5 ºC to reduce the exchange with water. The spectral analysis program Sparky 
was used for semiautomatic assignment of the NOESY cross-peaks and quantitative 
evaluation of the NOE intensities. Structural models based on NMR constraints were built 
with the program Sybyl (Tripos Inc) on the basis the Mtx:Tau RNA complex11 (PDB 
code:1Qc8). The ametantrone and neamine moieties were set at similar positions as the 
mitoxantrone and neomycin in their respective complexes with the RNA.9,11 Initial 
coordinates of the complex were energy minimized, submitted to a short run of molecular 
dynamics, and energy minimized again to optimized the geometry and eliminate steric 
contacts. These calculations were carried out with the program Sybyl using built-in force 
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Ligands with a preferred binding site in the bulged r gion of the stem-loop structure of Tau 
pre-mRNA have been identified by dynamic combinatori l chemistry.  
